Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672477 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
A Phase 4 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 4
- Development phase
- 237
- Enrollment target
NCT00672477 is a Phase 4 study that has completed, run by Bausch Health Americas. The registered enrollment target is 237 participants.
The verdict
NCT00672477, a Phase 4 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 237 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects.
Interventions
- DRUG Placebo
- DRUG Methylnaltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00672477
The ClinicalTrials.gov registry entry for NCT00672477 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00672477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00672477 about?
NCT00672477 is a clinical study titled "Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness". This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these ...
What is the current status of trial NCT00672477?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 237 participants. The study started on 2008-06. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00672477?
The interventions under investigation include: Placebo (DRUG), Methylnaltrexone (DRUG).
Who is sponsoring clinical trial NCT00672477?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.